WHAT IS CLAIMED IS:

1. A method for reducing the frequency of urination in a subject, comprising:

administering to a subject in need thereof a pharmaceutical composition comprising:

an active ingredient comprising one or more analgesic agents in an amount of 50-400 mg per agent, wherein said one or more analgesic agents are selected from the group consisting of aspirin, ibuprofen, naproxen, naproxen sodium, indomethacin, nabumetone, and acetaminophen,

wherein said pharmaceutical composition is formulated for extended-release such that said active ingredient is released continuously over a period of 5-24 hours.

2. The method of Claim 1, wherein said one or more analgesic agents comprises acetaminophen.

3. The method of Claim 1, wherein said active ingredient further comprises an antimuscarinic agent.

4. The method of Claim 1, wherein said active ingredient further comprises an antidiuretic agent.

5. The method of Claim 1, wherein said active ingredient further comprises a spasmolytic.

6. The method of Claim 1, wherein said active ingredient further comprises zolpidem.

7. The method of Claim 1, wherein said an active ingredient further comprises two additional agents selected from the group consisting of an antimuscarinic agent, an antidiuretic agent, a spasmolytic and zolpidem.

8. The method of Claim 1, wherein said pharmaceutical composition is formulated for extended-release such that said active ingredient is released continuously over a period of 5-8 hours.

9. The method of Claim 1, wherein said pharmaceutical composition is formulated for extended-release such that said active ingredient is released continuously over a period of 8-16 hours.

10. The method of Claim 1, wherein said pharmaceutical composition is formulated for extended-release such that said active ingredient is released continuously over a period of 16-24 hours.

11. The method of Claim 1, wherein said subject is a mammal.

12. A method for reducing the frequency of urination in a subject, comprising:

administering to a subject in need thereof a pharmaceutical composition comprising:

an active ingredient comprising one or more analgesic agents in an amount of 50-400 mg per agent, wherein said one or more analgesic agents are selected from the group consisting of aspirin, ibuprofen, naproxen, naproxen sodium, indomethacin, nabumetone, and acetaminophen,

wherein said pharmaceutical composition is formulated for extended release, characterized by a two-phase release profile in which 20-60% of said active ingredient is released within two hours of administration and remainder of said active ingredient is released continuously over a period of 5-24 hours.

13. The method of Claim 12, wherein said one or more analgesic agents comprises acetaminophen.

14. The method of Claim 12, wherein said active ingredient further comprises an antimuscarinic agent.

15. The method of Claim 12, wherein said active ingredient further comprises an antidiuretic agent.

16. The method of Claim 12, wherein said active ingredient further comprises a spasmolytic.

17. The method of Claim 12, wherein said active ingredient further comprises zolpidem.

18. The method of Claim 12, wherein said an active ingredient further comprises two additional agents selected from the group consisting of an antimuscarinic agent, an antidiuretic agent, a spasmolytic and zolpidem.

19. The method of Claim 12, wherein said remainder of said active ingredient is released continuously over a period of 5-8 hours.

20. The method of Claim 12, wherein said remainder of said active ingredient is released continuously over a period of 8-16 hours.

21. The method of Claim 12, wherein said remainder of said active ingredient is released continuously over a period of 16-24 hours.

22. A method for reducing the frequency of urination in a subject, comprising:

administering to a subject in need thereof an effective amount of botulinum toxin, wherein said botulinum toxin is administered by injection into a bladder muscle; and

orally administering to said subject a pharmaceutical composition comprising:

an active ingredient comprising one or more analgesic agents in a total amount of 50-400 mg per agent, wherein said one or more analgesic agents are selected from the group

consisting of aspirin, ibuprofen, naproxen, naproxen sodium, indomethacin, nabumetone, and acetaminophen,

wherein said pharmaceutical composition is formulated for extended-release.

23. The method of Claim 22, wherein said botulinum toxin is administered every 3 or 4 months and wherein said pharmaceutical composition is administered every day.

24. The method of Claim 22, wherein said active ingredient comprising one or more analgesic agents in an amount of 50-400 mg per agent and wherein said pharmaceutical composition is formulated for extended release such that said active ingredient is released continuously over a period of 5-16 hours.

25. The method of Claim 22, wherein said active ingredient comprising one or more analgesic agents in an amount of 50-400 mg per agent and wherein said pharmaceutical composition is formulated for extended release such that said active ingredient is released continuously over a period of 16-24 hours.

26. The method of Claim 22, wherein said active ingredient comprising one or more analgesic agents in an amount of 50-400 mg per agent and wherein said pharmaceutical composition is formulated for a two-phase, extended-release such that 20-60% of said active ingredient is released within two hours of administration and remainder of said active ingredient is released continuously over a period of 5-8 hours.

27. The method of Claim 22, wherein said active ingredient comprising one or more analgesic agents in an amount of 50-400 mg per agent and wherein said pharmaceutical composition is formulated for a two-phase, extended-release such that 20-60% of said active ingredient is released within two hours of administration and remainder of said active ingredient is released continuously over a period of 8-16 hours.

28. The method of Claim 22, wherein said active ingredient comprising one or more analgesic agents in an amount of 50-400 mg per agent and wherein said pharmaceutical composition is formulated for extended release, characterized by a two-phase release profile in which 20-60% of said active ingredient is released within two hours of administration and remainder of said active ingredient is released continuously over a period of 16-24 hours.

29. The method of Claim 22, wherein said one or more analgesic agents comprises acetaminophen.

30. The method of Claim 22, wherein said active ingredient further comprises an antimuscarinic agent.

31. The method of Claim 22, wherein said active ingredient further comprises an antidiuretic agent.

32. The method of Claim 22, wherein said active ingredient further comprises a spasmolytic.

33. The method of Claim 22, wherein said active ingredient further comprises zolpidem.

34. The method of Claim 22, wherein said an active ingredient further comprises two additional agents selected from the group consisting of an antimuscarinic agent, an antidiuretic agent, a spasmolytic and zolpidem.

35. A method for reducing the frequency of urination, comprising:

administering to a subject in need thereof an effective amount of one or more analgesic agents and an effective amount of zolpidem.

36. The method of Claim 35, wherein said one or more analgesic agents are formulated for extended release and wherein said zolpidem is formulated for immediate release.

37. The method of Claim 36, wherein said one or more analgesic agents are formulated for extended release such that said one or more analgesic agents are released continuously over a period of 5-24 hours.

38. The method of Claim 36, wherein said one or more analgesic agents are formulated for extended release, characterized by a two-phase release profile in which 20-60% of said one or more analgesic agents are released within two hours of administration and remainder of said one or more analgesic agents are released continuously over a period of 5-24 hours.

39. A method for reducing the frequency of urination in a subject, comprising:

administering to said subject a pharmaceutical composition comprising:

one or more analgesic agents; and

an antidiuretic,

wherein said one or more analgesic agents are formulated for delayed release and wherein said antidiuretic is formulated for immediate release.

40. The method of Claim 39, wherein said pharmaceutical composition further comprises an additional agent selected from the group consisting of an antimuscarinic agent, a spasmolytic and zolpidem, wherein said additional agent is formulated for delayed release.

41. A pharmaceutical composition, comprising:

an active ingredient comprising one or more analgesic agents in a total amount of 50-2000 mg;

zolpidem; and

a pharmaceutically acceptable carrier.

42. The pharmaceutical composition of Claim 41, wherein said one or more analgesic agents are formulated for extended release and wherein said zolpidem is formulated for immediate release.

43. The pharmaceutical composition of Claim 42, wherein said active ingredient comprising one or more analgesic agents in an amount of 50-400 mg per agent and wherein said one or more analgesic agents are formulated for extended release such that said one or more analgesic agents are released continuously over a period of 5-24 hours.

44. The pharmaceutical composition of Claim 42, wherein said active ingredient comprising one or more analgesic agents in an amount of 50-400 mg per agent and wherein said one or more analgesic agents are formulated for extended release, characterized by a two-phase release profile in which 20-60% of said one or more analgesic agents are released within two hours of administration and remainder of said one or more analgesic agents are released continuously over a period of 5-24 hours.

45. A pharmaceutical composition, comprising,

one or more analgesic agents; and

an antidiuretic,

wherein said one or more analgesic agents are formulated for delayed release and wherein said antidiuretic is formulated for immediate release.

46. The pharmaceutical composition of Claim 45, wherein said pharmaceutical composition further comprises an additional agent selected from the group consisting of an antimuscarinic agent, a spasmolytic and zolpidem, wherein said additional agent is formulated for delayed release.

CLAIMS

1. A method for reducing the frequency of urination in a subject, comprising:

administering to a subject in need thereof a pharmaceutical composition comprising:

an effective amount of an active ingredient comprising zolpidem and one or more analgesic agents.

2. The method of Claim 1, wherein said active ingredient further comprises an additional agent selected from the group consisting of antimuscarinic agents, antidiuretic agents, and spasmolytics.

3. The method of Claim 1 or 2, wherein said pharmaceutical composition is formulated for immediate release, delayed release, extended release or combinations thereof.

4. The method of Claim 1, wherein said one or more analgesic agents are formulated for extended release and wherein said zolpidem is formulated for immediate release.

5. The method of Claim 4, wherein said one or more analgesic agents are formulated for delayed release and wherein said zolpidem is formulated for immediate release.

6. A method for reducing the frequency of urination in a subject, comprising:

administering to a subject in need thereof an effective amount of botulinum toxin, wherein said botulinum toxin is administered by injection into a bladder muscle.

7. The method of Claim 6, further comprising:

administering to said subject a pharmaceutical composition comprising:

an effective amount of an active ingredient comprising one or more analgesic agents.

8. The method of Claim 7, wherein said one or more analgesic agents are selected from the group consisting of aspirin, ibuprofen, naproxen, naproxen sodium, indomethacin, nabumetone, and acetaminophen.

9. The method of Claim 7 or 8, wherein said active ingredient further comprises an additional agent selected from the group consisting of antimuscarinic agents, antidiuretic agents, spasmolytics and zolpidem.

10. The method of any one of Claims 7-9, wherein said pharmaceutical composition is formulated for immediate release, delayed release, extended release or combinations thereof.

11. A pharmaceutical composition, comprising:
an effective amount of an active ingredient comprising
zolpidem; and
one or more analgesic agents; and
a pharmaceutically acceptable carrier.

12. The pharmaceutical composition of Claim 11, wherein said active ingredient further comprises an additional agent selected from the group consisting of antimuscarinic agents, antidiuretic agents and spasmolytics.

13. The method of Claim 11 or 12, wherein said pharmaceutical composition is formulated for immediate release, delayed release, extended release or combinations thereof.

14. The pharmaceutical composition of any one of Claims 11-13, wherein said one or more analgesic agents are formulated for extended release and wherein said zolpidem is formulated for immediate release.

15. The pharmaceutical composition of any one of Claims 11-13, wherein said one or more analgesic agents are formulated for delayed release and wherein said zolpidem is formulated for immediate release.